Zastosowanie aptamerow w diagnostyce encefalopatii gabczastych zwierzat

• Autorzy: Szpechcinski A , Stepien A. , Izdebska M. , Grzanka A. , Jaskowski J.M.

Warianty tytułu

EN

Implementation of aptamers in the diagnosis of prion diseases

• Języki publikacji: PL

Abstrakty

EN

Prion diseases are a group of neurodegenerative conditions affecting both humans and animals. Among the methods used in prion disease diagnosis, immunoenzymatic tests as well as immunohistochemic and fluorescence analisis are distinguished. Currently, aptamers, which are single-stranded RNA or DNA oligonucleotides, are implemented with the above-mentioned methods. They play the role of artificial ligands that may be applied instead of widely used antibodies.

Słowa kluczowe

PL

aptamery; choroby prionowe; zastosowanie; encefalopatie gabczaste; diagnostyka; choroby zwierzat

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2007
• Tom: 63
• Numer: 10
• Strony: 1159-1162
• Opis fizyczny: s.1159-1162,bibliogr.

Twórcy

autor

Szpechcinski A

• Uniwersytet Mikolaja Kopernika w Toruniu, Collegium Medicum w Bydgoszczy, ul.Karlowicza 24, Bydgoszcz

autor

Stepien A.

autor

Izdebska M.

autor

Grzanka A.

autor

Jaskowski J.M.

Bibliografia

• 1.Aguzzi A.: Blood simple prion diagnostics. Nat. Med. 2001, 7, 289-290.
• 2.Aguzzi A., Heppner F. L.: Pathogenesis of prion diseases: a progress report. Cell Death Differ. 2000, 7, 889-902.
• 3.Bennion B. J., Daggett V.: Protein conformation and diagnostic tests: the prion protein. Clin. Chem. 2002, 48, 2105-2114.
• 4.Chakraborty C., Nandi S., Jana S.: Prion disease: a deadly disease for protein misfolding. Cur. Pharm. Biotechnol. 2005, 6, 167-177.
• 5.Eulberg D., Buchner K., Maasch C., Klussmann S.: Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist. Nucleic Acids Res. 2005, 33, e45.
• 6.Fournier J. G., Grigoriev B.: Prion diseases: contribution of high-resolution immunomorphology. J. Cell. Mol. Med. 2001, 5, 367-377.
• 7.Gofflot S., El M. B., Zorzi D., Melen L., Roels S., Quatpers D., Grassi J., Vanopdenbosch E., Heinen E., Zorzi W.: Immuno-quantitative polymerase chain reaction for detection and quantitation of prion protein. J. Immunoassay Immunochem. 2004, 25, 241-258.
• 8.Harris D. A.: Cellular biology of prion diseases. Clin. Microbio. Rev. 1999, 12, 429-444.
• 9.James W.: Aptamers, [w:] Meyers R. A. (red.): Encyclopedia of Analytical Chemistry. John Wiley&Sons Ltd, Chichester 2000, 4848-4871.
• 10. Jayasena S. D.: Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 1999, 45, 1628-1650.
• 11. Jenison R. D., Gill S. C., Pardi A., Polisky B.: Isozyme-specific inhibition of protein kinase C by RNA aptamers. J. Bio. Chem. 1994, 269, 32051-32054.
• 12.Kelly J. W.: The environmental dependency of protein folding best explains prion and amyloid diseases. Proc. Natl. Acad. Sci. USA 1998, 95, 930-932.
• 13.Klein M. A., Frigg R., Flechsig E., Raeber A. J., Kalinke U., Bluethmann H., Bootz F., Suter M., Zinkernagel R. M., Aguzzi A.: A crucial role for B cells in neuroinvasive scrapie. Nature 1997, 390, 687-690.
• 14.Lasmezas C. I., Deslys J. P., Robain O., Jaegly A., Beringue V., Peyrin J. M., Fournier J. G., Hauw J. J., Rossier J., Dormont D.: Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 1997, 275, 402-405.
• 15.McCarthy A.: Archemix. Nucleic Acids platforms. Chem. Biol. 2002, 9, 663-665.
• 16.Maclean D., Baldwin J. J., Ivanov V. T., Kato Y., Shaw A., Schenider P., Gordon E. M.: Glossary of Terms Used in Combinatorial Chemistry. Pure Appl. Chem. 1999, 71, 2349-2365.
• 17.Phan A. T., Kuryavyi V., Ma J. B., Faure A., Andreola M. L., Patel D. J.: An interlocked dimeric parallel-stranded DNA quadruplex: a potent inhibitor of HIV-1 integrase. Proc. Natl. Acad. Sci. USA 2005, 102, 634-639.
• 18.Pieken W. A., Olsen D. B., Benseler F., Aurup H., Eckstein F.: Kinetic characterisation of ribonuclease-resistant 2'-modified hammerhead ribozymes. Science 1991, 253, 314-317.
• 19.Proske D., Gilch S., Wopfner F., Schatzl H. M., Winnacker E. L., Famulok M.: Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem. 2002, 3, 717-725.
• 20.Prusiner S. B.: Prions. Proc. Natl. Acad. Sci. USA 1998, 95, 13363-13383.
• 21.Rhie A., Kirby L., Sayer N., Wellesley R., Disterer P., Sylvester I., Gill A., Hope J., James W., Tahiri-Alaoui A.: Characterization of 2'-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J. Biol. Chem. 2003, 278, 39697-39705.
• 22.Safar J. G., DeArmond S. J., Kociuba K., Deering C., Didorenko S., Bouzamondo-Bernstein E., Prusiner S. B., Tremblay P.: Prion clearance in bigenic mice. J. Gen. Virol. 2005, 86, 2913-2923.
• 23.Safar J. G., Scott M., Monaghan J., Deering C., Didorenko S., Vergara J., Ball H., Legname G., Leclerc E., Solforosi L., Serban H., Groth D., Burton D. R., Prusiner S. B., Williamson R. A.: Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat. Biotechnol. 2002, 20, 1147-1150.
• 24.Sayer N. M., Cubin M., Rhie A., Bullock M., Tahiri-Alaoui A., James W.: Structural determinants of conformationally selective, prion-binding aptamers. J. Biol. Chem. 2004, 279, 13102-13109.
• 25.Schatzl H. M., Da Costa M., Taylor L., Cohen F. E., Prusiner S. B.: Prion protein gene variation among primates. J. Mol. Biol. 1995, 245, 362-374.
• 26.Schonberger L. B.: New variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Infec. Dis. Clin. North Am. 1998, 12, 111-121.
• 27.Tuerk C., Gold L.: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249, 505-510.
• 28.Unruh J. R., Gokulrangan G., Wilson G. S., Johnson C. K.: Fluorescence properties of fluorescein, tetramethylrhodamine and Texas Red linked to a DNA aptamer. Photochem. Photobiol. 2005, 81, 682-690.
• 29.Weissmann C., Aguzzi A.: Approaches to therapy of prion diseases. Ann. Rev. Med. 2005, 56, 321-344.
• 30.Wilson D. S., Szostak J. W.: In vitro selection of functional nucleic acids. Ann. Rev. Biochem. 1999, 68, 611-647.